Advanced Gastric Cancer Clinical Trials

15 recruiting

Advanced Gastric Cancer Trials at a Glance

22 actively recruiting trials for advanced gastric cancer are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in Shanghai, Seoul, and Naples. Lead sponsors running advanced gastric cancer studies include Jiangsu HengRui Medicine Co., Ltd., Qilu Hospital of Shandong University, and Yonsei University.

Browse advanced gastric cancer trials by phase

Treatments under study

About Advanced Gastric Cancer Clinical Trials

Looking for clinical trials for Advanced Gastric Cancer? There are currently 15 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced Gastric Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced Gastric Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 22 trials

Recruiting
Not Applicable

Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy

Locally Advanced Gastric Cancer
Guihua Wang404 enrolled1 locationNCT06597227
Recruiting
Phase 2

Safety and Efficacy of Leucine-Restricted Diet Combined With Chemotherapy and Immunotherapy in Advanced Gastric Cancer

Advanced Gastric Cancer
Qilu Hospital of Shandong University73 enrolled1 locationNCT07537348
Recruiting
Phase 2

PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer

Advanced Gastric CancerSHR1701
The First Affiliated Hospital of Zhengzhou University78 enrolled1 locationNCT07294664
Recruiting
Phase 1

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Advanced Gastric CancerMetastatic Solid TumorsAdvanced Non-squamous Non-small-cell Lung Cancer+4 more
BeiGene514 enrolled17 locationsNCT06585488
Recruiting
Phase 2

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled139 locationsNCT06157892
Recruiting
Phase 1

Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer

Advanced Gastric Cancer
Jia Wei18 enrolled1 locationNCT07298200
Recruiting

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

HER2-positive Advanced Gastric CancerHER2-positive Gastroesophageal Junction Adenocarcinoma
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company257 enrolled76 locationsNCT05993234
Recruiting
Not Applicable

Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients

Advanced Breast CancerEarly Breast CancerAdvanced Lung Cancer+5 more
Ulsan University Hospital414 enrolled5 locationsNCT07405931
Recruiting
Phase 2

Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers

Advanced Breast CancerAdvanced Gastric CancerAdvanced Urothelial Cancer+1 more
UNICANCER400 enrolled1 locationNCT07259226
Recruiting
Phase 2

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

Gastroesophageal Junction AdenocarcinomaMetastatic Gastric CancerAdvanced Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.351 enrolled2 locationsNCT07102901
Recruiting
Phase 2

Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.350 enrolled1 locationNCT06947291
Recruiting
Phase 1

HS-10502 Combination Treatment in Patients With Advanced Solid Tumors

Advanced Breast CancerAdvanced Prostate CancerTNBC+3 more
Jiangsu Hansoh Pharmaceutical Co., Ltd.157 enrolled1 locationNCT06769425
Recruiting
Not Applicable

Fecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric Cancer

Advanced Gastric Cancer
Changhai Hospital124 enrolled1 locationNCT06346093
Recruiting

The Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric Cancer

Gastric AdenocarcinomaLocally Advanced Gastric Cancer
The First Hospital of Jilin University300 enrolled1 locationNCT06881043
Recruiting

A Multi-center Real-world Efficacy and Safety of Trastuzumab-deruxtecan in Advanced Gastric Cancer

Advanced Gastric Cancer
Yonsei University300 enrolled1 locationNCT06767436
Recruiting

Zolbetuximab Claudin18.2 Positive, HER2 Negative, Advanced Gastric Cancer

Advanced Gastric Cancer
Yonsei University80 enrolled1 locationNCT06767449
Recruiting

First-Line and Neoadjuvant Immunotherapy for Gastric Cancer

Locally Advanced Gastric CarcinomaAdvanced Gastric Cancer
Qilu Hospital of Shandong University500 enrolled1 locationNCT06727981
Recruiting
Phase 1Phase 2

Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy

HER2-positive Advanced Gastric Cancer
Kangbuk Samsung Hospital47 enrolled1 locationNCT05640830
Recruiting

Machine Learning-driven Noninvasive Screening of Transcriptomics Liquid Biopsies for Early Diagnosis of Occult Peritoneal Metastases in Locally Advanced Gastric Cancer

1. Locally Advanced Gastric Cancer (LAGC): The Primary Condition Under Investigation is Locally Advanced Gastric Cancer, Which Refers to Stomach
Qun Zhao300 enrolled1 locationNCT06478394
Recruiting
Phase 2

A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma

Advanced Gastric Cancer
Shanghai Zhongshan Hospital71 enrolled1 locationNCT04799548